Research programme: stem cell therapies - NeoStem Oncology

Drug Profile

Research programme: stem cell therapies - NeoStem Oncology

Alternative Names: MotorGraft

Latest Information Update: 30 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator California Stem Cell; Families of SMA; Johns Hopkins University; University of California at Irvine
  • Developer ALS Therapy Development Institute; Families of SMA; Johns Hopkins University; NeoStem Oncology; University of California at Irvine
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Spinal muscular atrophy

Most Recent Events

  • 08 May 2014 NeoStem acquires California Stem Cell and renames it NeoStem Oncology
  • 30 Nov 2010 California Stem Cell files an IND application with the FDA in USA for Spinal muscular atrophy
  • 02 Feb 2010 Preclinical development in Amyotrophic lateral sclerosis is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top